Literature DB >> 24281063

Lung cancer: cetuximab, you're fired.

M Teresa Villanueva.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24281063     DOI： 10.1038/nrclinonc.2013.227

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Authors:  Edward S Kim; Marcus Neubauer; Allen Cohn; Lee Schwartzberg; Lawrence Garbo; John Caton; Francisco Robert; Craig Reynolds; Terry Katz; Sreeni Chittoor; Lorinda Simms; Scott Saxman
Journal:  Lancet Oncol       Date:  2013-11-12       Impact factor: 41.316
  1 in total
  2 in total

1.  Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.

Authors:  Rita De Santis; Antonio Rosi; Anna Maria Anastasi; Caterina Chiapparino; Claudio Albertoni; Barbara Leoni; Angela Pelliccia; Daniela Santapaola; Valeria Carollo; Emanuele Marra; Luigi Aurisicchio; Brunilde Arseni; Maria Lucrezia Pacello; Gabriella Palmieri; Simone Battella; Fiorella Petronzelli; Ferdinando Maria Milazzo
Journal:  Oncotarget       Date:  2014-10-15

2.  Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.

Authors:  Yang Zhang; Jie Yang; Manhua Ding; Liantao Li; Zheng Lu; Qing Zhang; Junnian Zheng
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.